List of works - David Michael Andrews

Applications of the amino-Cope rearrangement: synthesis of tetrahydropyran, delta-lactone and piperidine targets.

scientific article published on 26 January 2005

Collaborative practices for medicinal chemistry research across the big pharma and not-for-profit interface

scientific article published on 28 January 2014

Compound Passport Service: supporting corporate collection owners in open innovation

scientific article published on 29 June 2015

Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors

scientific article

Design and campaign synthesis of pyridine-based histone deacetylase inhibitors

scientific article published on 22 March 2008

Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease

scientific article published in December 2002

Design and synthesis of spiro-cyclopentenyl and spiro-[1,3]-dithiolanyl substituted pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease

scientific article published in May 2003

Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies

scientific article published on 9 January 2017

Design of a Chemical Probe for the Bromodomain and Plant Homeodomain Finger-Containing (BRPF) Family of Proteins.

scientific article published on 17 July 2017

Discovery of potent, selective small molecule inhibitors of α-subtype of type III phosphatidylinositol-4-kinase (PI4KIIIα).

scientific article published on 4 June 2015

Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode

scientific article

Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors

scientific article

Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors

scientific article

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen [...]

scientific article

Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate

scientific article

Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase α- but not β-inhibit the phosphatidylinositol signaling cascade and cancer cell proliferation

scientific article

Progress towards a public chemogenomic set for protein kinases and a call for contributions

scientific article

Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase

scientific article

Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C virus NS3/4A protease

scientific article published on December 2002

Pyrrolidine-5,5-trans-lactams. 2. The use of X-ray crystal structure data in the optimization of P3 and P4 substituents

scientific article

Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A protease

scientific article

Pyrrolidine-5,5-trans-lactams. 5. Pharmacokinetic optimization of inhibitors of hepatitis C virus NS3/4A protease

scientific article published on 01 November 2003

Short and versatile route to a key intermediate for lactacystin synthesis

scientific article published on 01 February 2003

Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer

scientific article published on 02 July 2011

Solid-phase synthesis of O-mannosylated peptides: two strategies compared

scientific article published on 01 August 1993

Solid-phase synthesis of a range of O-phosphorylated peptides by post-assembly phosphitylation and oxidation

scientific article published on 01 November 1991

The creation and characterisation of a National Compound Collection: the Royal Society of Chemistry pilot

scientific article published on 23 February 2016

The design of potent, non-peptidic inhibitors of hepatitis C protease

scientific article published in April 2003

The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing

scientific article

List of works by David Michael Andrews

Applications of the amino-Cope rearrangement: synthesis of tetrahydropyran, delta-lactone and piperidine targets.

Collaborative practices for medicinal chemistry research across the big pharma and not-for-profit interface

Compound Passport Service: supporting corporate collection owners in open innovation

Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors

Design and campaign synthesis of pyridine-based histone deacetylase inhibitors

Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease

Design and synthesis of spiro-cyclopentenyl and spiro-[1,3]-dithiolanyl substituted pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease

Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies

Design of a Chemical Probe for the Bromodomain and Plant Homeodomain Finger-Containing (BRPF) Family of Proteins.

Discovery of potent, selective small molecule inhibitors of α-subtype of type III phosphatidylinositol-4-kinase (PI4KIIIα).

Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode

Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors

Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen [...]

Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate

Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase α- but not β-inhibit the phosphatidylinositol signaling cascade and cancer cell proliferation

Progress towards a public chemogenomic set for protein kinases and a call for contributions

Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase

Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C virus NS3/4A protease

Pyrrolidine-5,5-trans-lactams. 2. The use of X-ray crystal structure data in the optimization of P3 and P4 substituents

Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A protease

Pyrrolidine-5,5-trans-lactams. 5. Pharmacokinetic optimization of inhibitors of hepatitis C virus NS3/4A protease

Short and versatile route to a key intermediate for lactacystin synthesis

Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer

Solid-phase synthesis of O-mannosylated peptides: two strategies compared

Solid-phase synthesis of a range of O-phosphorylated peptides by post-assembly phosphitylation and oxidation

The creation and characterisation of a National Compound Collection: the Royal Society of Chemistry pilot

The design of potent, non-peptidic inhibitors of hepatitis C protease

The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing